Dr Richard
Goodwin

Richard has built an industry-leading molecular tissue imaging capability that is innovative in the breadth of applications and project impact. This has been achieved by seeking new emerging science and collaborating extensively with the technology and data analysis inventors. His group combine high dimensionality mass spectrometry tissue imaging with more established digital pathology to provide novel insights into drug discovery and disease progression. Scaling the use of the molecular imaging technologies brings new data mining challenges. To address this challenge AstraZeneca are working with Cancer Research UK Grand Challenge team to develop novel computational methods for large cohort imaging studies. These technologies are starting to form the beginning of a tissue section based multi- ‘omics analysis that integrates spatial relationships in unprecedented detail.